FEAM welcomes the opportunity to respond to the open consultation on the Pharmaceutical Strategy for Europe. The COVID-19 pandemic has illustrated the importance of strengthening the EU’s health research and biomedical R&D landscape. While biomedical innovation has now received an additional boost in the EU’s pandemic recovery strategy, carrying the European health research enterprise forward will require addressing challenges across the life cycle of health technologies – from basic research to commercialization and eventually to access for patients. As we have learned during the past few months, an important degree of flexibility to define and update priorities, and a sound regulatory system for approval of medicines, including a rapid and robust mechanism to approve drugs in emergency situations -for example in pandemics- will be essential to address future crises.[…]
Leggi la dichiarazione della FEAM (Federation of European Academies of Medicine) sulle nuove strategie farmaceutiche in Europa qui: FEAM Position Statement on the new Pharmaceutical Strategy for Europe
Evento organizzato dalla FEAM European Biomedical Policy Forum and Cancer Research UK.